reports
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-13...
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology. About the Study The article, titled “TFC-1326 Compound Reduces Clinical Signs of Skin Aging: Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial,” highlights the groundbreaking efficacy of Sirona’s proprietary compound ...
SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Produc...
SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Product Rollout VANCOUVER, British Columbia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update: Dear Shareholders, We are thrilled to provide an update on our efforts to bring our innovative cosmeceutical portfolio to global markets, with the initial launch set for early 2025. The commercialization of our first cosmetic product, a serum containing our GlycoProteMim™ active is progressing smoothly, in line with the timeline outlined in o...
GlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Res...
GlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Research Report VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare's newly published research report, "Novel Treatments for Age-Related Skin Problems." The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market. The research highlights GlycoProteMim alongside other prominent ...
Sirona Biochem Engages Stonegate Healthcare Partners
Sirona Biochem Engages Stonegate Healthcare Partners VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services. Leveraging Stonegate’s extensive global network of corporate and institutional investor relationships, Stonegate has begun an evaluation of Sirona’s anti-aging ingredient, GlycoProteMimTM, to effectively ass...
SIRONA BIOCHEM Corporate Update April 2024
SIRONA BIOCHEM Corporate Update April 2024 VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update: Dear shareholders, We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem’s path forward. AGM Last week, during our Annual General Meeting (AGM), we successfully gained another year of backing for our management team. Although it's common for many shareholders to abstain from voting, we're pleased to report that we'...
Sirona Biochem Announces Close of Private Placement
Sirona Biochem Announces Close of Private Placement VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Vancouver, British Columbia – April 4, 2024 – . (TSX-V: SBM) (Frankfurt: ZSB) (“Sirona”) has closed its private placement (Private Placement”) for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the “Units”) at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of i...
Sirona Biochem Announces 2023 Annual Meeting Results
Sirona Biochem Announces 2023 Annual Meeting Results VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 26,722,196, representing 10.52% of Sirona's issued and outstanding Common Shares. All matters put forward to shareholders for consideration and approval, as set out in the ...
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Agin...
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions. The chose...
Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™...
Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025 VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its journey. A recent exclusive video interview featuring Dr. Geraldine Deliencourt-Godefroy, Sirona's Chief Scientific Officer, has been released by the Investing News Network. In this interview, Dr. Deliencourt-Godefroy unveils Sirona's ambitious plans to introduce its innovative anti-aging product, GlycoProteMimTM, to t...
Sirona Biochem Provides Update on Loan
Sirona Biochem Provides Update on Loan VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announce that, further to its news release on January 29, 2024, it has entered into an amendment to the demand grid promissory note dated September 22, 2023 (the “Amended Note”) with 0906462 B.C. Ltd. (the “Lender”). The Amended Note evidences a loan in the aggregate principal amount of up to $1,000,000 (the “Loan”). Pursuant to the terms and conditions of the Amended Note: (a) the Loan is repayable on demand by the L...
Sirona Biochem Engages Global Beauty Consulting
Sirona Biochem Engages Global Beauty Consulting VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) has announced its partnership with Global Beauty Consulting – Cosmetics Laboratory (GBC), under the leadership of CEO Gaël Boutry, a distinguished French formulator. GBC is currently developing an exclusive premium formulation for GlycoProteMimTM in anticipation of its launch in the first quarter of 2025. GBC has a history of working with Sirona Biochem on the formulation of TFC-1067 for clinical development. This...
Sirona Biochem Announces Loan
Sirona Biochem Announces Loan VANCOUVER, British Columbia, Jan. 29, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announced that it has entered into a demand grid promissory note (the “Note”) with 0906462 B.C. Ltd. (the “Lender”) for a loan in the aggregate principal amount of up to $1,000,000 (the “Loan”). Pursuant to the terms and conditions of the Note: (a) the Loan is repayable on demand by the Lender; (b) the Loan bears interest at a rate of 12% per annum, calculated yearly not in advance; and (c) the Company has agreed to, subject to...
Sirona Biochem Initiates Private Placement
Sirona Biochem Initiates Private Placement VANCOUVER, British Columbia, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V:SBM) (FSE: ZSB) (OTC: SRBCF) (the "Company") is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company at a price of $0.10 CAD per Unit (a "Unit") for gross proceeds of up to CAD$1,000,000 (the "Private Placement"). Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of is...
CORRECTION -- Sirona Biochem Corporate Update January 2024
CORRECTION -- Sirona Biochem Corporate Update January 2024 VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), please note that in the 8th paragraph of the letter, the company plans to launch its first product early in the 1st quarter of 2025, not the 1st quarter of 2024 as previously stated. The corrected release follows: Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased ...
Sirona Biochem Corporate Update January 2024
Sirona Biochem Corporate Update January 2024 VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem's path forward. Trademark of TFC-1326 as GlycoProteMim We recently trademarked TFC-1326 as GlycoProteMimTM. This branding decision aims to distinguish our anti-aging active ingredient in a competitive...
Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™
Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™ VANCOUVER, Canada, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is proud to introduce Sirona LaboratoriesTM - a wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMimTM. Dr. Howard Verrico, CEO and founder of Sirona Biochem, expressed his enthusiasm for the major milestone, stating that the establishment of Sirona Laboratories is meant to not just shape the future of the company, but to revolu...
Sirona Biochem Initiates GlycoProteMim™ Trademark for Anti-Aging Molec...
Sirona Biochem Initiates GlycoProteMim™ Trademark for Anti-Aging Molecule TFC-1326 VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), is making a strategic move in the world of advanced skincare solutions. Today, the company announces the trademarking of its groundbreaking anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim™. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim™, filed with the In...
Sirona Biochem Announces Change of Auditor
Sirona Biochem Announces Change of Auditor VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC:SRBCF) (the “Company") announces that it has changed its auditors from DeVisser Gray LLP (the “Former Auditor”) Davidson and Company (the “Successor Auditor”) effective October 25, 2023 and the board of directors of the Company appointed the Successor Auditor as the Company’s auditor effective October 25, 2023 until the next Annual General Meeting of the Company. There were no reservations in the Former Auditor’s audit reports for t...
Sirona Biochem Announces Payment of Convertible Debenture Interests in...
Sirona Biochem Announces Payment of Convertible Debenture Interests in Shares NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES VANCOUVER, British Columbia, Oct. 20, 2023 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announces that pursuant to the 12% unsecured, convertible debentures in the principal amount of $1,500,000 (the “Debentures”) previously issued on April 20, 2023, the Company will issue common shares in the capital of the Company (the “Common Shares”) in satisfaction of interest payments on the outstanding Debentures (...
Sirona Biochem Initiates Significant Corporate Changes
Sirona Biochem Initiates Significant Corporate Changes VANCOUVER, British Columbia, June 15, 2022 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to inform about several significant corporate changes currently in preparation: Now that Sirona Biochem has closed an the next steps for sustainable and rapid growth of the company are initiated. The Board has begun a strategic review of every facet of the company including management, organizational structure, project pipeline, financial position and the exchanges on which the Sirona shares are listed. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.